Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma

Pathology

Volumn 42, Issue 3, 2010, Pages 224-228

  Huang, Wen Wei ^a   Tsao, Shih Ming ^b   Lai, Chun Liang ^a   Su, Cheng Chuan ^a,c   Tseng, Chih En ^a,c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

CEA; Cyfra 21 1; Her 2 neu; Lung cancer; Pleural fluid; Tumour marker

Indexed keywords

EID: 77950305235     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313021003631320     Document Type: Article

References (29)

1. Website of the Department of Health, Executive Yuan, Taiwan. http:// www.doh.gov.tw (accessed 20 April 2009).
2. Chang SC, Lee LN, Kuo SH, et al. Survival of patients with malignant pleural effusion. J Formos Med Assoc 1987; 86: 672-678
3. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479-485
4. Yang SP, Luh KT, Kuo SH, et al. Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration: a 30-year consecutive study. Jpn J Clin Oncol 1984; 14: 7-19.
5. Ger LP, Hsu WL, Chen KT, et al. Risk factors of lung cancer by histological category in Taiwan. Anticancer Res 1993; 13: 1491-1500
6. Marel M, Stastny B, Melinova L, et al. Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest 1995; 107: 1598-1603
7. Prakash BS, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985; 60: 158-164
8. Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86: 1488-1495
9. Miedouge M, Rouzaud P, Salama G, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 1999; 81: 1059-1065
10. Gu P, Huang G, Chen Y, et al. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal 2007; 21: 398-405.
11. Gaspar MJ, De Miguel J, García Díaz JD, et al. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Anticancer Res 2008; 28: 2947-2952
12. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712
13. Weiner DB, Nordberg J, Robinson R, et al. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 1990; 50: 421-425
14. Hung TL, Chen FF, Liu JM, et al. Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. Clin Cancer Res 2003; 9: 2605-2612
15. Porcel JM, Salud A, Vives M, et al. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions. Clin Biochem 2005; 38: 1031-1033
16. Krouwer JS. Cumulative distribution analysis graphs: an alternative to ROC curves. Clin Chem 1987; 33: 2305-2306
17. Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001; 31: 9-16.
18. Toumbis M, Rasidakis A, Passalidou E, et al. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res 1996; 16: 2101-2104
19. Fuhrman C, Duche JC, Chouaid C, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem 2000; 33: 405-410
20. Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005; 128: 2298-2303
21. Shitrit D, Zingerman B, Shitrit AB, et al. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005; 10: 501-507
22. Ebert W, Dienemann H, Fateh-Moghadam A, et al. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem 1994; 32: 189-199
23. Valdes L, Alvarez D, San Jose E, et al. Tuberculous pleurisy: a study of 254 patients. Arch Intern Med 1998; 158: 2017-2021
24. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, et al. Interferongamma in 388 immunocompromised and immunocompetent patients for diagnosing pleural tuberculosis. Eur Respir J 1996; 9: 2635-2639
25. Garcia-Pachon E, Padilla-Navas I, Dosda MD, et al. Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest 1997; 111: 643-647
26. Riantawan P, Sangsayan P, Bangpattanasiri K, et al. Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion. Respiration 2000; 67: 24-29
27. Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J 1997; 10: 1907-1913
28. DiBonito L, Falconieri G, Colautti I, et al. The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytologica 1992; 36: 329-332
29. Cascinu S, Del Ferro E, Barbanti I, et al. Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Oncol 1997; 20: 247-250